Biomea Fusion Q1 net loss narrows to $12.4 million; cash runway into Q1 2027
Biomea Fusion reported a first-quarter 2026 net loss of $12.4 million, down from $29.3 million a year earlier, as research and development and general and administrative expenses fell. Cash, cash equivalents and restricted cash were $45.1 million at March 31, 2026, down from $56.2 million at December 31, 2025, and the company said its cash runway extends into the first quarter of 2027.
Key points
- Net loss attributable to common stockholders was $12.4 million, or $0.17 per share, versus $29.3 million, or $0.80 per share, in Q1 2025.
- R&D expenses were $9.1 million versus $22.9 million; G&A expenses were $3.7 million versus $6.8 million.
- Cash, cash equivalents and restricted cash were $45.1 million at March 31, 2026, versus $56.2 million at December 31, 2025.
- Cash runway is projected into the first quarter of 2027; initial 28-day weight reduction data for BMF-650 is expected in Q2 2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.